Pharmacological Profile and Research Applications of a-MSH,

Pharmacological Profile and Research Applications of a-MSH, Amide: Mechanisms, Clinical Value, and Future Directions

Introduction
Alpha-melanocyte-stimulating hormone (a-MSH), amide, is a synthetic peptide analog of the endogenous neuropeptide a-MSH, which is derived from the proopiomelanocortin (POMC) precursor. a-MSH, amide, is characterized by its C-terminal amidation, a modification that enhances its biological stability and receptor affinity compared to its non-amidated counterpart (Hadley & Dorr, 2006, Peptides). The peptide exerts its effects primarily through activation of melanocortin receptors (MCRs), a family of G protein-coupled receptors (GPCRs) that include five subtypes (MC1R–MC5R), each with distinct tissue distributions and physiological roles (Gantz & Fong, 2003, Endocrine Reviews).

The mechanism of action of a-MSH, amide, involves binding to MCRs, leading to activation of adenylate cyclase, increased intracellular cyclic adenosine monophosphate (cAMP), and subsequent modulation of downstream signaling pathways. These pathways regulate a variety of physiological processes, including pigmentation, energy homeostasis, inflammation, and immune responses (Getting, 2006, Peptides). The synthetic a-MSH, amide, is widely utilized in research settings to probe melanocortin signaling, investigate anti-inflammatory and immunomodulatory effects, and explore therapeutic potential in diverse disease models.

[Related: abt199] Clinical Value and Applications
a-MSH, amide, has garnered significant interest due to its pleiotropic effects and potential therapeutic applications. Its most well-characterized role is in the regulation of skin pigmentation via MC1R activation on melanocytes, stimulating eumelanin synthesis and providing photoprotection (Yamaguchi et al., 2007, Pigment Cell Research). Beyond pigmentation, a-MSH, amide, exhibits potent anti-inflammatory and immunomodulatory properties, making it a candidate for the treatment of inflammatory and autoimmune disorders.

Preclinical and early clinical studies have demonstrated the efficacy of a-MSH analogs in models of inflammatory bowel disease (IBD), multiple sclerosis, and rheumatoid arthritis, where they attenuate pro-inflammatory cytokine production and reduce tissue damage (Getting, 2006, Peptides; Brzoska et al., 2008, Endocrine, Metabolic & Immune Disorders Drug Targets). Additionally, a-MSH, amide, has shown promise in neuroprotection, particularly in models of ischemic stroke and neurodegenerative diseases, by mitigating oxidative stress and apoptosis (Delgado et al., 1998, Annals of the New York Academy of Sciences).

[Related: aprotinin sigma] In dermatology, a-MSH, amide, is being explored for its ability to induce tanning and protect against ultraviolet (UV) radiation-induced DNA damage, with potential applications in photoprotection and prevention of skin cancers (D'Orazio et al., 2013, Photochemistry and Photobiology). Its appetite-suppressing effects via MC4R activation have also led to investigations in obesity and metabolic syndrome.

Key Challenges and Pain Points Addressed
Current treatments for inflammatory and autoimmune diseases often involve broad immunosuppression, which can lead to increased susceptibility to infections and malignancies. a-MSH, amide, offers a targeted approach by modulating specific immune pathways without global immunosuppression (Getting, 2006, Peptides). Its ability to downregulate pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6, while upregulating anti-inflammatory mediators like IL-10, addresses the need for safer, more selective anti-inflammatory agents (Brzoska et al., 2008, Endocrine, Metabolic & Immune Disorders Drug Targets).

[Related: anhydrous tetracycline] In dermatology, conventional photoprotective agents provide only external protection and may not prevent UV-induced mutagenesis. a-MSH, amide, enhances endogenous melanin production, offering intrinsic photoprotection and reducing the risk of UV-induced skin damage (Yamaguchi et al., 2007, Pigment Cell Research).

Furthermore, the peptide's neuroprotective effects address the lack of effective therapies for acute and chronic neurodegenerative conditions, where inflammation and oxidative stress play central roles in pathogenesis (Delgado et al., 1998, Annals of the New York Academy of Sciences).

Literature Review
Several key studies have elucidated the pharmacological properties and therapeutic potential of a-MSH, amide and its analogs:

1. **Hadley, M.E., & Dorr, R.T. (2006). Peptides, 27(6), 1195-1203.**
This review outlines the structure-activity relationships of melanocortin peptides, emphasizing the enhanced stability and receptor selectivity conferred by C-terminal amidation. The authors discuss the clinical development of a-MSH analogs for photoprotection and anti-inflammatory applications.

2. **Getting, S.J. (2006). Peptides, 27(2), 329-336.**
This article details the anti-inflammatory actions of melanocortins, including a-MSH, in various animal models of inflammation. The review highlights the peptide's ability to inhibit leukocyte migration, cytokine production, and tissue injury.

3. **Brzoska, T., et al. (2008). Endocrine, Metabolic & Immune Disorders Drug Targets, 8(3), 252-259.**
The authors provide an overview of the immunomodulatory effects of a-MSH, focusing on its role in autoimmune diseases. The review discusses preclinical evidence supporting its use in experimental models of multiple sclerosis and rheumatoid arthritis.

4. **Delgado, M., et al. (1998). Annals of the New York Academy of Sciences, 840, 361-374.**
This study investigates the neuroprotective effects of a-MSH in models of cerebral ischemia and neurodegeneration. The results demonstrate reduced neuronal apoptosis and improved functional outcomes following peptide administration.

5. **Yamaguchi, Y., et al. (2007). Pigment Cell Research, 20(2), 190-199.**
The authors examine the role of a-MSH in melanogenesis and photoprotection. The study provides evidence for the peptide's ability to stimulate eumelanin synthesis and protect against UV-induced DNA damage.

6. **D'Orazio, J.A., et al. (2013). Photochemistry and Photobiology, 89(1), 233-238.**
This paper discusses the potential of a-MSH analogs as pharmacological tanning agents and their role in reducing the risk of melanoma by enhancing melanin-mediated photoprotection.

7. **Gantz, I., & Fong, T.M. (2003). Endocrine Reviews, 24(5), 687-707.**
A comprehensive review of melanocortin receptors, their physiological functions, and the therapeutic implications of targeting these receptors with peptide agonists such as a-MSH, amide.

Experimental Data and Results
Experimental studies have consistently demonstrated the efficacy of a-MSH, amide, in modulating immune and inflammatory responses. In a murine model of colitis, systemic administration of a-MSH, amide, significantly reduced disease severity, as evidenced by decreased histological inflammation and lower levels of pro-inflammatory cytokines (Getting, 2006, Peptides). Similarly, in experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis, treatment with a-MSH, amide, resulted in delayed onset and reduced severity of neurological symptoms, correlating with suppressed T-cell activation and cytokine production (Brzoska et al., 2008, Endocrine, Metabolic & Immune Disorders Drug Targets).

In dermatological research, topical or systemic administration of a-MSH, amide, has been shown to increase melanin content in human skin explants and animal models, providing enhanced resistance to UV-induced erythema and DNA damage (Yamaguchi et al., 2007, Pigment Cell Research; D'Orazio et al., 2013, Photochemistry and Photobiology).

Neuroprotective effects have been demonstrated in rodent models of cerebral ischemia, where a-MSH, amide, administration reduced infarct size, improved neurological outcomes, and decreased markers of oxidative stress and apoptosis (Delgado et al., 1998, Annals of the New York Academy of Sciences). These findings support the therapeutic potential of a-MSH, amide, in acute and chronic neurodegenerative conditions.

Usage Guidelines and Best Practices
a-MSH, amide, is typically supplied as a lyophilized powder and should be reconstituted in sterile water or appropriate buffer prior to use. For in vitro studies, concentrations in the range of 10 nM to 1 μM are Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 44 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11551765